Filters close
Released: 23-Feb-2024 2:45 PM EST
MD Anderson acquires inducible switch technologies for cell therapy
University of Texas MD Anderson Cancer Center

MD Anderson has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDE switch and GoCAR platforms. As a result, MD Anderson may incorporate these technologies into its own cell therapy programs as well as make them available for licensing to interested parties.

Released: 21-Feb-2024 4:00 PM EST
MD Anderson researchers receive over $25.5 million in CPRIT funding
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.

   
Released: 21-Feb-2024 12:00 PM EST
MD Anderson Research Highlights for February 21, 2024
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson offer insights into drug-drug interactions for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes; patient-derived xenograft models as a viable translational research tool in early-phase clinical trials; a novel gene expression signature to stratify patients with bladder cancer; a potential therapeutic target to overcome treatment resistance in multiple myeloma; a role for mutant p53 in protecting against ferroptosis in triple-negative breast cancer; and diet modifications to improve treatment outcomes in FLT3-mutated AML.

   
Newswise: Biomarker-directed combination effective in immunotherapy-resistant lung cancer
12-Feb-2024 5:00 PM EST
Biomarker-directed combination effective in immunotherapy-resistant lung cancer
University of Texas MD Anderson Cancer Center

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.

12-Feb-2024 5:05 PM EST
Immunotherapy before surgery leads to promising long-term survival in sarcoma patients
University of Texas MD Anderson Cancer Center

Patients with soft-tissue sarcoma treated with neoadjuvant, or pre-surgical, immunotherapy had very little residual tumor at the time of surgery and promising long-term survival, according to Phase II trial results published today in Nature Cancer by researchers at The University of Texas MD Anderson Cancer Center

Released: 7-Feb-2024 5:00 PM EST
MD Anderson and C-Biomex sign collaborative research agreement to co-develop CBT-001 radioligand therapy
University of Texas MD Anderson Cancer Center

MD Anderso and C-Biomex today announced a strategic collaboration to co-develop CBT-001, a radioligand targeting the CA9 cancer biomarker.

Released: 7-Feb-2024 12:00 PM EST
MD Anderson Research Highlights for February 7, 2024
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

   
Newswise: MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine worldwide
Released: 30-Jan-2024 10:05 AM EST
MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine worldwide
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center today announced the signing of an agreement with the International Atomic Energy Agency (IAEA) to become an IAEA Collaborating Centre.

Released: 25-Jan-2024 12:00 PM EST
MD Anderson Research Highlights for January 25, 2024
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

Newswise: Cervical cancer rates rising in low-income U.S. counties
24-Jan-2024 5:05 PM EST
Cervical cancer rates rising in low-income U.S. counties
University of Texas MD Anderson Cancer Center

Women in low-income areas of the U.S. face a stark rise in cervical cancer incidence and mortality, according to a new study led by researchers from The University of Texas MD Anderson Cancer Center.

Released: 24-Jan-2024 3:00 PM EST
MD Anderson to host 2024 Cancer Neuroscience Symposium
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center will host the 2024 Cancer Neuroscience Symposium, Feb. 28 - Mar. 1, in collaboration the journal Advanced Biology.

   
17-Jan-2024 5:00 AM EST
CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies
University of Texas MD Anderson Cancer Center

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

Released: 10-Jan-2024 12:00 PM EST
MD Anderson Research Highlights for January 10, 2024
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments at MD Anderson include insights into the effects of the gut microbiome on remote tumors, a screening strategy for ovarian cancer early detection, a combination approach to overcome PARP inhibitor resistance, further understanding of ferroptosis resistance, a ferroptosis-based strategy for overcoming treatment resistance in acute myeloid leukemia (AML), potential targets for p53 mutations that lead to cancer progression, a signature for more accurately predicting risk in patients with AML given low-intensity treatments, and a prognostic tool to stratify patients with colorectal cancer.

5-Jan-2024 5:05 PM EST
Vaccine demonstrates potential in delaying relapse of KRAS-mutated pancreatic and colorectal cancers
University of Texas MD Anderson Cancer Center

A vaccine showed potential to prevent relapse of KRAS-mutated pancreatic and colorectal cancers for patients who had previously undergone surgery, according to a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center.

   
Newswise: Nidhi Sahni receives TAMEST Mary Beth Maddox Award for research in molecular pathways of cancer progression
Released: 18-Dec-2023 9:00 AM EST
Nidhi Sahni receives TAMEST Mary Beth Maddox Award for research in molecular pathways of cancer progression
University of Texas MD Anderson Cancer Center

Nidhi Sahni, Ph.D., associate professor of Epigenetics and Molecular Carcinogenesis at The University of Texas MD Anderson Cancer Center, has been awarded the 2024 Mary Beth Maddox Award and Lectureship in cancer research from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST).

   
Released: 13-Dec-2023 12:00 PM EST
MD Anderson Research Highlights for December 13, 2023
University of Texas MD Anderson Cancer Center

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention.

   
11-Dec-2023 3:30 PM EST
ASH: Mantle cell lymphoma patients see improved outcomes with oral combination of ibrutinib and venetoclax
University of Texas MD Anderson Cancer Center

The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III SYMPATICO trial were presented at the 2023 American Society of Hematology (ASH) Annual Meeting.

Newswise: ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
9-Dec-2023 10:30 AM EST
ASH: Novel combination therapy significantly reduces spleen volume in patients with myelofibrosis
University of Texas MD Anderson Cancer Center

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

Newswise: ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder
8-Dec-2023 11:00 AM EST
ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder
University of Texas MD Anderson Cancer Center

The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood disorder called nonadvanced system mastocytosis.

Newswise: elias_jabbour.jpg.resize.405.575.high.jpg
8-Dec-2023 1:15 PM EST
ASH: Novel menin inhibitors show promise for patients with advanced acute myeloid leukemias
University of Texas MD Anderson Cancer Center

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.



close
0.15031